BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Schoepfer AM, Trummler M, Seeholzer P, Criblez DH, Seibold F. Accuracy of four fecal assays in the diagnosis of colitis. Dis Colon Rectum. 2007;50:1697-1706. [PMID: 17762964 DOI: 10.1007/s10350-007-0303-9] [Cited by in Crossref: 61] [Cited by in F6Publishing: 62] [Article Influence: 4.4] [Reference Citation Analysis]
Number Citing Articles
1 Saini SD, Waljee AK, Higgins PD. Cost utility of inflammation-targeted therapy for patients with ulcerative colitis. Clin Gastroenterol Hepatol 2012;10:1143-51. [PMID: 22610010 DOI: 10.1016/j.cgh.2012.05.003] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.7] [Reference Citation Analysis]
2 Schoepfer AM, Beglinger C, Straumann A, Trummler M, Renzulli P, Seibold F. Ulcerative colitis: correlation of the Rachmilewitz endoscopic activity index with fecal calprotectin, clinical activity, C-reactive protein, and blood leukocytes. Inflamm Bowel Dis. 2009;15:1851-1858. [PMID: 19462421 DOI: 10.1002/ibd.20986] [Cited by in Crossref: 194] [Cited by in F6Publishing: 187] [Article Influence: 16.2] [Reference Citation Analysis]
3 Sherwood RA. Faecal markers of gastrointestinal inflammation. J Clin Pathol 2012;65:981-5. [DOI: 10.1136/jclinpath-2012-200901] [Cited by in Crossref: 40] [Cited by in F6Publishing: 40] [Article Influence: 4.4] [Reference Citation Analysis]
4 Radillo O, Pascolo L, Martelossi S, Dal Bo S, Ventura A. Fecal Calprotectin: Diagnostic Accuracy of the Immunochromatographic CalFast Assay in a Pediatric Population. J Clin Lab Anal 2016;30:500-5. [PMID: 26879689 DOI: 10.1002/jcla.21886] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
5 Lamb CA, Mansfield JC. Measurement of faecal calprotectin and lactoferrin in inflammatory bowel disease. Frontline Gastroenterol. 2011;2:13-18. [PMID: 23904968 DOI: 10.1136/fg.2010.001362] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 2.3] [Reference Citation Analysis]
6 Hall B, Holleran G, Mcnamara D. Current applications and potential future role of wireless capsule technology in Crohn’s disease. Scandinavian Journal of Gastroenterology 2014;49:1275-84. [DOI: 10.3109/00365521.2014.962606] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
7 Sarsu SB, Erbagci AB, Ulusal H, Karakus SC, Bulbul ÖG. The Place of Calprotectin, Lactoferrin, and High-Mobility Group Box 1 Protein on Diagnosis of Acute Appendicitis with Children. Indian J Surg 2017;79:131-6. [PMID: 28442839 DOI: 10.1007/s12262-015-1441-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
8 Lehmann FS, Burri E, Beglinger C. The role and utility of faecal markers in inflammatory bowel disease. Therap Adv Gastroenterol. 2015;8:23-36. [PMID: 25553077 DOI: 10.1177/1756283x14553384] [Cited by in Crossref: 95] [Cited by in F6Publishing: 37] [Article Influence: 15.8] [Reference Citation Analysis]
9 Nanau RM, Neuman MG. Metabolome and inflammasome in inflammatory bowel disease. Transl Res. 2012;160:1-28. [PMID: 22687960 DOI: 10.1016/j.trsl.2011.08.006] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 2.2] [Reference Citation Analysis]
10 Anderson N, Suliman I, Bandaletova T, Obichere A, Lywood R, Loktionov A. Protein biomarkers in exfoliated cells collected from the human rectal mucosa: implications for colorectal disease detection and monitoring. Int J Colorectal Dis. 2011;26:1287-1297. [PMID: 21698353 DOI: 10.1007/s00384-011-1263-z] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
11 Caccaro R, D’incà R, Martinato M, Pont ED, Pathak S, Frigo AC, Sturniolo GC. Fecal lactoferrin and intestinal permeability are effective non-invasive markers in the diagnostic work-up of chronic diarrhea. Biometals 2014;27:1069-76. [DOI: 10.1007/s10534-014-9745-4] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
12 Magro F, Sousa P, Ministro P. C-reactive protein in Crohn's disease: how informative is it? Expert Rev Gastroenterol Hepatol. 2014;8:393-408. [PMID: 24635486 DOI: 10.1586/17474124.2014.893821] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 2.1] [Reference Citation Analysis]
13 Burri E, Manz M, Rothen C, Rossi L, Beglinger C, Lehmann FS. Monoclonal antibody testing for fecal calprotectin is superior to polyclonal testing of fecal calprotectin and lactoferrin to identify organic intestinal disease in patients with abdominal discomfort. Clin Chim Acta. 2013;416:41-47. [PMID: 23178549 DOI: 10.1016/j.cca.2012.11.008] [Cited by in Crossref: 20] [Cited by in F6Publishing: 24] [Article Influence: 2.2] [Reference Citation Analysis]
14 Ma C, Battat R, Parker CE, Khanna R, Jairath V, Feagan BG. Update on C-reactive protein and fecal calprotectin: are they accurate measures of disease activity in Crohn’s disease? Expert Review of Gastroenterology & Hepatology 2019;13:319-30. [DOI: 10.1080/17474124.2019.1563481] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
15 Bennike T, Birkelund S, Stensballe A, Andersen V. Biomarkers in inflammatory bowel diseases: Current status and proteomics identification strategies. World J Gastroenterol 2014; 20(12): 3231-3244 [PMID: 24696607 DOI: 10.3748/wjg.v20.i12.3231] [Cited by in CrossRef: 70] [Cited by in F6Publishing: 63] [Article Influence: 10.0] [Reference Citation Analysis]
16 Zhou XL, Xu W, Tang XX, Luo LS, Tu JF, Zhang CJ, Xu X, Wu QD, Pan WS. Fecal lactoferrin in discriminating inflammatory bowel disease from irritable bowel syndrome: a diagnostic meta-analysis. BMC Gastroenterol. 2014;14:121. [PMID: 25002150 DOI: 10.1186/1471-230x-14-121] [Cited by in Crossref: 19] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
17 Menees SB, Powell C, Kurlander J, Goel A, Chey WD. A meta-analysis of the utility of C-reactive protein, erythrocyte sedimentation rate, fecal calprotectin, and fecal lactoferrin to exclude inflammatory bowel disease in adults with IBS. Am J Gastroenterol. 2015;110:444-454. [PMID: 25732419 DOI: 10.1038/ajg.2015.6] [Cited by in Crossref: 170] [Cited by in F6Publishing: 138] [Article Influence: 28.3] [Reference Citation Analysis]
18 Jang HW, Kim HS, Park SJ, Hong SP, Kim TI, Kim WH, Cheon JH. Accuracy of three different fecal calprotectin tests in the diagnosis of inflammatory bowel disease. Intest Res 2016;14:305-13. [PMID: 27799881 DOI: 10.5217/ir.2016.14.4.305] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 3.2] [Reference Citation Analysis]
19 Schoepfer AM, Beglinger C, Straumann A, Trummler M, Vavricka SR, Bruegger LE, Seibold F. Fecal calprotectin correlates more closely with the Simple Endoscopic Score for Crohn's disease (SES-CD) than CRP, blood leukocytes, and the CDAI. Am J Gastroenterol. 2010;105:162-169. [PMID: 19755969 DOI: 10.1038/ajg.2009.545] [Cited by in Crossref: 344] [Cited by in F6Publishing: 316] [Article Influence: 28.7] [Reference Citation Analysis]
20 van Rheenen PF, Van de Vijver E, Fidler V. Faecal calprotectin for screening of patients with suspected inflammatory bowel disease: diagnostic meta-analysis. BMJ 2010;341:c3369. [PMID: 20634346 DOI: 10.1136/bmj.c3369] [Cited by in Crossref: 392] [Cited by in F6Publishing: 351] [Article Influence: 35.6] [Reference Citation Analysis]
21 Kalantari H, Taheri A, Yaran M. Fecal calprotectin is a useful marker to diagnose ulcerative colitis from irritable bowel syndrome. Adv Biomed Res. 2015;4:85. [PMID: 26015911 DOI: 10.4103/2277-9175.156647] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
22 Wang S, Wang Z, Shi H, Heng L, Juan W, Yuan B, Wu X, Wang F. Faecal calprotectin concentrations in gastrointestinal diseases. J Int Med Res. 2013;41:1357-1361. [PMID: 23723365 DOI: 10.1177/0300060513488499] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 1.9] [Reference Citation Analysis]
23 Petryszyn P, Staniak A, Wolosianska A, Ekk-cierniakowski P. Faecal calprotectin as a diagnostic marker of inflammatory bowel disease in patients with gastrointestinal symptoms: meta-analysis. European Journal of Gastroenterology & Hepatology 2019;31:1306-12. [DOI: 10.1097/meg.0000000000001509] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
24 Rodríguez-moranta F, Lobatón T, Rodríguez-alonso L, Guardiola J. Calprotectina fecal en el diagnóstico de enfermedades inflamatorias. Gastroenterología y Hepatología 2013;36:400-6. [DOI: 10.1016/j.gastrohep.2012.10.008] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
25 Ho GT, Lee HM, Brydon G, Ting T, Hare N, Drummond H, Shand AG, Bartolo DC, Wilson RG, Dunlop MG. Fecal calprotectin predicts the clinical course of acute severe ulcerative colitis. Am J Gastroenterol. 2009;104:673-678. [PMID: 19262524 DOI: 10.1038/ajg.2008.119] [Cited by in Crossref: 97] [Cited by in F6Publishing: 97] [Article Influence: 8.1] [Reference Citation Analysis]
26 Hosseini SV, Jafari P, Taghavi SA, Safarpour AR, Rezaianzadeh A, Moini M, Mehrabi M. Fecal Calprotectin is an Accurate Tool and Correlated to Seo Index in Prediction of Relapse in Iranian Patients With Ulcerative Colitis. Iran Red Crescent Med J 2015;17:e22796. [PMID: 25793117 DOI: 10.5812/ircmj.22796] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
27 Prell C, Nagel D, Freudenberg F, Schwarzer A, Koletzko S. Comparison of three tests for faecal calprotectin in children and young adults: a retrospective monocentric study. BMJ Open. 2014;4:e004558. [PMID: 24793248 DOI: 10.1136/bmjopen-2013-004558] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
28 Waljee AK, Lipson R, Wiitala WL, Zhang Y, Liu B, Zhu J, Wallace B, Govani SM, Stidham RW, Hayward R, Higgins PDR. Predicting Hospitalization and Outpatient Corticosteroid Use in Inflammatory Bowel Disease Patients Using Machine Learning. Inflamm Bowel Dis. 2017;24:45-53. [PMID: 29272474 DOI: 10.1093/ibd/izx007] [Cited by in Crossref: 36] [Cited by in F6Publishing: 35] [Article Influence: 18.0] [Reference Citation Analysis]
29 Muthas D, Reznichenko A, Balendran CA, Böttcher G, Clausen IG, Kärrman Mårdh C, Ottosson T, Uddin M, MacDonald TT, Danese S, Berner Hansen M. Neutrophils in ulcerative colitis: a review of selected biomarkers and their potential therapeutic implications. Scand J Gastroenterol 2017;52:125-35. [PMID: 27610713 DOI: 10.1080/00365521.2016.1235224] [Cited by in Crossref: 73] [Cited by in F6Publishing: 66] [Article Influence: 14.6] [Reference Citation Analysis]
30 Grellet A, Mila H, Heilmann RM, Feugier A, Gruetzner N, Suchodolski JS, Steiner JM, Chastant-Maillard S. Effect of age, gestation and lactation on faecal IgA and calprotectin concentrations in dogs. J Nutr Sci 2014;3:e41. [PMID: 26101610 DOI: 10.1017/jns.2014.44] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
31 Nancey S, Boschetti G, Moussata D, Cotte E, Peyras J, Cuerq C, Haybrard J, Charlois AL, Mialon A, Chauvenet M. Neopterin is a novel reliable fecal marker as accurate as calprotectin for predicting endoscopic disease activity in patients with inflammatory bowel diseases. Inflamm Bowel Dis. 2013;19:1043-1052. [PMID: 23511035 DOI: 10.1097/mib.0b013e3182807577] [Cited by in Crossref: 69] [Cited by in F6Publishing: 29] [Article Influence: 8.6] [Reference Citation Analysis]
32 Boon GJ, Day AS, Mulder CJ, Gearry RB. Are faecal markers good indicators of mucosal healing in inflammatory bowel disease? World J Gastroenterol 2015; 21(40): 11469-11480 [PMID: 26523111 DOI: 10.3748/wjg.v21.i40.11469] [Cited by in CrossRef: 35] [Cited by in F6Publishing: 34] [Article Influence: 5.8] [Reference Citation Analysis]
33 De Vos M, Louis EJ, Jahnsen J, Vandervoort JG, Noman M, Dewit O, D’haens GR, Franchimont D, Baert FJ, Torp RA. Consecutive fecal calprotectin measurements to predict relapse in patients with ulcerative colitis receiving infliximab maintenance therapy. Inflamm Bowel Dis. 2013;19:2111-2117. [PMID: 23883959 DOI: 10.1097/mib.0b013e31829b2a37] [Cited by in Crossref: 131] [Cited by in F6Publishing: 49] [Article Influence: 18.7] [Reference Citation Analysis]
34 Benítez JM, García-Sánchez V. Faecal calprotectin: Management in inflammatory bowel disease. World J Gastrointest Pathophysiol 2015; 6(4): 203-209 [PMID: 26600978 DOI: 10.4291/wjgp.v6.i4.203] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
35 Kopylov U, Rosenfeld G, Bressler B, Seidman E. Clinical utility of fecal biomarkers for the diagnosis and management of inflammatory bowel disease. Inflamm Bowel Dis. 2014;20:742-756. [PMID: 24562174 DOI: 10.1097/01.mib.0000442681.85545.31] [Cited by in Crossref: 99] [Cited by in F6Publishing: 37] [Article Influence: 16.5] [Reference Citation Analysis]
36 Ayling RM. New faecal tests in gastroenterology. Ann Clin Biochem. 2012;49:44-54. [PMID: 22113956 DOI: 10.1258/acb.2011.011150] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 2.0] [Reference Citation Analysis]
37 Niaz B, Saeed F, Ahmed A, Imran M, Maan AA, Khan MKI, Tufail T, Anjum FM, Hussain S, Suleria HAR. Lactoferrin (LF): a natural antimicrobial protein. International Journal of Food Properties 2019;22:1626-41. [DOI: 10.1080/10942912.2019.1666137] [Cited by in Crossref: 16] [Cited by in F6Publishing: 4] [Article Influence: 8.0] [Reference Citation Analysis]
38 Schaffer T, Schoepfer AM, Seibold F; Swiss IBD Cohort Study Group. Serum ficolin-2 correlates worse than fecal calprotectin and CRP with endoscopic Crohn's disease activity. J Crohns Colitis 2014;8:1125-32. [PMID: 24636141 DOI: 10.1016/j.crohns.2014.02.014] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
39 Theede K, Kiszka-kanowitz M, Mertz Nielsen A, Nordgaard-lassen I. The correlation between fecal calprotectin, simple clinical colitis activity index and biochemical markers in ulcerative colitis during high-dose steroid treatment. Scandinavian Journal of Gastroenterology 2014;49:418-23. [DOI: 10.3109/00365521.2014.883427] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 2.7] [Reference Citation Analysis]
40 Sipponen T, Savilahti E, Kärkkäinen P, Kolho KL, Nuutinen H, Turunen U, Färkkilä M. Fecal calprotectin, lactoferrin, and endoscopic disease activity in monitoring anti-TNF-alpha therapy for Crohn’s disease. Inflamm Bowel Dis. 2008;14:1392-1398. [PMID: 18484671 DOI: 10.1002/ibd.20490] [Cited by in Crossref: 162] [Cited by in F6Publishing: 156] [Article Influence: 13.5] [Reference Citation Analysis]
41 Kwapisz L, Mosli M, Chande N, Yan B, Beaton M, Micsko J, Mennill PW, Barnett W, Bax K, Ponich T, Howard J, Tirolese A, Lannigan R, Gregor J. Rapid fecal calprotectin testing to assess for endoscopic disease activity in inflammatory bowel disease: A diagnostic cohort study. Saudi J Gastroenterol 2015;21:360-6. [PMID: 26655130 DOI: 10.4103/1319-3767.170948] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
42 Turkay C, Kasapoglu B. Noninvasive methods in evaluation of inflammatory bowel disease: where do we stand now? An update. Clinics (Sao Paulo). 2010;65:221-231. [PMID: 20186307 DOI: 10.1590/S1807-59322010000200015] [Cited by in Crossref: 14] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
43 Li X, Conklin L, Alex P. New serological biomarkers of inflammatory bowel disease. World J Gastroenterol 2008; 14(33): 5115-5124 [PMID: 18777587 DOI: 10.3748/wjg.14.5115] [Cited by in CrossRef: 47] [Cited by in F6Publishing: 45] [Article Influence: 3.6] [Reference Citation Analysis]
44 Zhou FS, Gao N, Sun X, Jiang XY, Chen JJ, Mao QQ, Zhong L. C-reactive protein/abumin ratio is a useful biomarker for predicting the mucosal healing in the Crohn disease: A retrospective study. Medicine (Baltimore) 2021;100:e24925. [PMID: 33725853 DOI: 10.1097/MD.0000000000024925] [Reference Citation Analysis]
45 Adam V, Zitka O, Dolezal P, Zeman L, Horna A, Hubalek J, Sileny J, Krizkova S, Trnkova L, Kizek R. Lactoferrin Isolation Using Monolithic Column Coupled with Spectrometric or Micro-Amperometric Detector. Sensors (Basel) 2008;8:464-87. [PMID: 27879717 DOI: 10.3390/s8010464] [Cited by in Crossref: 31] [Cited by in F6Publishing: 24] [Article Influence: 2.4] [Reference Citation Analysis]
46 De Vos M, Dewit O, D’Haens G, Baert F, Fontaine F, Vermeire S, Franchimont D, Moreels T, Staessen D, Terriere L. Fast and sharp decrease in calprotectin predicts remission by infliximab in anti-TNF naïve patients with ulcerative colitis. J Crohns Colitis. 2012;6:557-562. [PMID: 22398050 DOI: 10.1016/j.crohns.2011.11.002] [Cited by in Crossref: 98] [Cited by in F6Publishing: 92] [Article Influence: 9.8] [Reference Citation Analysis]
47 Gisbert JP, McNicholl AG, Gomollon F. Questions and answers on the role of fecal lactoferrin as a biological marker in inflammatory bowel disease. Inflamm Bowel Dis. 2009;15:1746-1754. [PMID: 19363798 DOI: 10.1002/ibd.20920] [Cited by in Crossref: 65] [Cited by in F6Publishing: 62] [Article Influence: 5.9] [Reference Citation Analysis]
48 Caccaro R, D’Incá R, Sturniolo GC. Clinical utility of calprotectin and lactoferrin as markers of inflammation in patients with inflammatory bowel disease. Expert Rev Clin Immunol. 2010;6:551-558. [PMID: 20594128 DOI: 10.1586/eci.10.26] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.1] [Reference Citation Analysis]
49 Sydora MJ, Sydora BC, Fedorak RN. Validation of a point-of-care desk top device to quantitate fecal calprotectin and distinguish inflammatory bowel disease from irritable bowel syndrome. J Crohns Colitis. 2012;6:207-214. [PMID: 22325175 DOI: 10.1016/j.crohns.2011.08.008] [Cited by in Crossref: 35] [Cited by in F6Publishing: 39] [Article Influence: 3.5] [Reference Citation Analysis]
50 Rufo PA, Denson LA, Sylvester FA, Szigethy E, Sathya P, Lu Y, Wahbeh GT, Sena LM, Faubion WA. Health supervision in the management of children and adolescents with IBD: NASPGHAN recommendations. J Pediatr Gastroenterol Nutr. 2012;55:93-108. [PMID: 22516861 DOI: 10.1097/mpg.0b013e31825959b8] [Cited by in Crossref: 70] [Cited by in F6Publishing: 27] [Article Influence: 7.8] [Reference Citation Analysis]
51 Tan KS. New insights on classification, identification, and clinical relevance of Blastocystis spp. Clin Microbiol Rev 2008;21:639-65. [PMID: 18854485 DOI: 10.1128/CMR.00022-08] [Cited by in Crossref: 358] [Cited by in F6Publishing: 194] [Article Influence: 27.5] [Reference Citation Analysis]
52 Schoepfer AM, Schaffer T, Seibold-Schmid B, Müller S, Seibold F. Antibodies to flagellin indicate reactivity to bacterial antigens in IBS patients. Neurogastroenterol Motil. 2008;20:1110-1118. [PMID: 18694443 DOI: 10.1111/j.1365-2982.2008.01166.x] [Cited by in Crossref: 69] [Cited by in F6Publishing: 74] [Article Influence: 5.3] [Reference Citation Analysis]
53 Lopez RN, Leach ST, Lemberg DA, Duvoisin G, Gearry RB, Day AS. Fecal biomarkers in inflammatory bowel disease: Faecal biomarkers. Journal of Gastroenterology and Hepatology 2017;32:577-82. [DOI: 10.1111/jgh.13611] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 7.3] [Reference Citation Analysis]
54 Sipponen T, Kärkkäinen P, Savilahti E, Kolho K, Nuutinen H, Turunen U, Färkkilä M. Correlation of faecal calprotectin and lactoferrin with an endoscopic score for Crohn’s disease and histological findings. Alimentary Pharmacology & Therapeutics 2008;28:1221-9. [DOI: 10.1111/j.1365-2036.2008.03835.x] [Cited by in Crossref: 210] [Cited by in F6Publishing: 211] [Article Influence: 16.2] [Reference Citation Analysis]
55 Andréasson K, Saxne T, Scheja A, Bartosik I, Mandl T, Hesselstrand R. Faecal levels of calprotectin in systemic sclerosis are stable over time and are higher compared to primary Sjögren's syndrome and rheumatoid arthritis. Arthritis Res Ther 2014;16:R46. [PMID: 24499541 DOI: 10.1186/ar4475] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
56 Schoepfer AM, Beglinger C, Straumann A, Safroneeva E, Romero Y, Armstrong D, Schmidt C, Trummler M, Pittet V, Vavricka SR. Fecal calprotectin more accurately reflects endoscopic activity of ulcerative colitis than the Lichtiger Index, C-reactive protein, platelets, hemoglobin, and blood leukocytes. Inflamm Bowel Dis. 2013;19:332-341. [PMID: 23328771 DOI: 10.1097/mib.0b013e3182810066] [Cited by in Crossref: 164] [Cited by in F6Publishing: 79] [Article Influence: 20.5] [Reference Citation Analysis]
57 Chen CC, Chang CJ, Lin TY, Lai MW, Chao HC, Kong MS. Usefulness of fecal lactoferrin in predicting and monitoring the clinical severity of infectious diarrhea. World J Gastroenterol 2011; 17(37): 4218-4224 [PMID: 22072854 DOI: 10.3748/wjg.v17.i37.4218] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 12] [Article Influence: 1.9] [Reference Citation Analysis]
58 Manolakis AC, Kapsoritakis AN, Georgoulias P, Tzavara C, Valotassiou V, Kapsoritaki A, Potamianos SP. Moderate performance of serum S100A12, in distinguishing inflammatory bowel disease from irritable bowel syndrome. BMC Gastroenterol. 2010;10:118. [PMID: 20946669 DOI: 10.1186/1471-230x-10-118] [Cited by in Crossref: 25] [Cited by in F6Publishing: 16] [Article Influence: 2.3] [Reference Citation Analysis]
59 Otten CM, Kok L, Witteman BJ, Baumgarten R, Kampman E, Moons KG, de Wit NJ. Diagnostic performance of rapid tests for detection of fecal calprotectin and lactoferrin and their ability to discriminate inflammatory from irritable bowel syndrome. Clin Chem Lab Med. 2008;46:1275-1280. [PMID: 18597588 DOI: 10.1515/cclm.2008.246] [Cited by in Crossref: 31] [Cited by in F6Publishing: 27] [Article Influence: 2.4] [Reference Citation Analysis]
60 Wright EK, De Cruz P, Gearry R, Day AS, Kamm MA. Fecal biomarkers in the diagnosis and monitoring of Crohn's disease. Inflamm Bowel Dis. 2014;20:1668-1677. [PMID: 24918319 DOI: 10.1097/mib.0000000000000087] [Cited by in Crossref: 38] [Cited by in F6Publishing: 13] [Article Influence: 6.3] [Reference Citation Analysis]
61 Wright EK, Kamm MA, De Cruz P, Hamilton AL, Ritchie KJ, Keenan JI, Leach S, Burgess L, Aitchison A, Gorelik A. Comparison of Fecal Inflammatory Markers in Crohn's Disease. Inflamm Bowel Dis. 2016;22:1086-1094. [PMID: 26818420 DOI: 10.1097/MIB.0000000000000671] [Cited by in Crossref: 14] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
62 Kennedy NA, Clark A, Walkden A, Chang JC, Fascí-Spurio F, Muscat M, Gordon BW, Kingstone K, Satsangi J, Arnott ID. Clinical utility and diagnostic accuracy of faecal calprotectin for IBD at first presentation to gastroenterology services in adults aged 16-50 years. J Crohns Colitis. 2015;9:41-49. [PMID: 25135754 DOI: 10.1016/j.crohns.2014.07.005] [Cited by in Crossref: 10] [Cited by in F6Publishing: 16] [Article Influence: 1.7] [Reference Citation Analysis]